Sanofi partners with ScionxBio on long-acting RNA

Endpoints News reported on October 19, 2026, that ScionxBio has signed a deal with Sanofi—its first partnership since ScionxBio separated from Eleven Therapeutics.

ScionxBio is a preclinical biotechnology company developing long-acting xRNA medicines, initially for cardiometabolic diseases. Its platform is designed to keep therapeutic protein production going for weeks or months, potentially reducing how often patients need treatment.

The companies’ announcement, as reflected in the available report summary, does not specify the deal’s financial terms, exact research target, or development milestones.